This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Continue to Hold Veracyte Stock in Your Portfolio Now?
by Zacks Equity Research
VCYT's Decipher growth and strong cash position bolster its outlook, but Biopharma headwinds and macro risks loom.
Is it Prudent to Retain Charles River Stock in Your Portfolio Now?
by Zacks Equity Research
CRL sees momentum in drug discovery and safety services, but macro pressures and currency headwinds threaten growth.
Should Franklin U.S. Mid Cap Multifactor Index ETF (FLQM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FLQM
BD Partners With Waters to Build High-Volume Diagnostics Leader
by Zacks Equity Research
BDX collaborates with Waters in a $17.5B deal to form a diagnostics powerhouse targeting $9B in revenues by 2030.
Will Robust MedSurg Performance Fuel Boston Scientific's Q2 Earnings?
by Zacks Equity Research
BSX eyes strong Q2 with MedSurg momentum, solid Cardiovascular growth and benefits from key tech acquisitions.
ABT to Report Q2 Earnings: CGM and Cardiac Devices in Focus
by Zacks Equity Research
Abbott eyes Q2 growth with strong CGM momentum, cardiac device wins and resilient performance across key segments.
Bio-Rad Stock Climbs Following the Launch of Four ddPCR Platforms
by Zacks Equity Research
BIO surges 4% as the Stilla acquisition fuels the launch of four ddPCR systems, expanding to 400K+ assay offerings.
Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
InspireMD Launches CGuard Prime Carotid Stent System in the U.S.
by Zacks Equity Research
NSPR unveils FDA-approved CGuard Prime in the United States, targeting safer carotid procedures and stroke prevention.
Here's Why You Should Add Cencora Stock to Your Portfolio Now
by Zacks Equity Research
COR gains on strong GLP-1 and specialty drug growth, but margin pressure and fierce competition pose ongoing risks.
Reasons to Add Fresenius Medical Stock to Your Portfolio Now
by Zacks Equity Research
FMS continues to gain traction on the back of acquisitions & partnerships. A tough regulatory environment raises concerns.
ABT's FreeStyle Libre 3 Plus Now Available in Canada: Stock to Rise?
by Zacks Equity Research
Abbott debuts FreeStyle Libre 3 Plus in Canada, enhancing diabetes care with the world's smallest glucose sensor.
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
by Zacks Equity Research
CNMD stock rides high on strong recurring revenues, margin gains, and surgical product growth despite supply and cybersecurity challenges.
Should You Continue to Hold STERIS Stock in Your Portfolio Now?
by Zacks Equity Research
STE rides on strong Healthcare and AST growth, but macro pressures and customer consolidation cloud its outlook.
Is it Worth Adding Boston Scientific Stock to Your Portfolio Now?
by Zacks Equity Research
BSX rides on strong MedSurg growth and strategic acquisitions amid currency headwinds.
AMN Stock Gains Post Latest Deals With symplr to Boost Operations
by Zacks Equity Research
AMN Healthcare sells Smart Square to symplr for $75 million and forms a new technology partnership aimed at boosting scheduling efficiency.
Here's Why You Should Add PacBio Stock to Your Portfolio Now
by Zacks Equity Research
PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset macroeconomic concerns and drive 2025 growth.
Alcon Stock Gains Following UNITY VCS' Approval in Canada
by Zacks Equity Research
ALC's UNITY VCS gets Canada's approval, advancing surgical precision with faster, more efficient technology.
Should You Continue to Hold Thermo Fisher Stock in Your Portfolio Now?
by Zacks Equity Research
TMO's growth via acquisitions and product launches is strong, but macro pressures and FX headwinds cloud the outlook.
Paysafe and Champion Homes have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
PSFE earns Bull of the Day with deep value and rising earnings, while SKY's short surge and weak outlook land it as Bear of the Day.
Should You Invest in the First Trust Consumer Staples AlphaDEX ETF (FXG)?
by Zacks Equity Research
Sector ETF report for FXG
Stereotaxis Reports Positive Initial Data From MAGiC Catheter Trial
by Zacks Equity Research
STXS posts first peer-reviewed results for its MAGiC catheter, showing 94% efficacy and strong safety in arrhythmia treatment.
Should You Retain Henry Schein Stock in Your Portfolio Right Now?
by Zacks Equity Research
Investors are optimistic about HSIC, owing to the strong Henry Schein One performance. However, macro headwinds and fierce competition pose challenges.
Quest Diagnostics Stock Climbs 27.3% in a Year: What's Fueling It?
by Zacks Equity Research
DGX stock surges 27.3% in a year, fueled by Advanced Diagnostics, key acquisitions and expanding health plan ties.
Intuitive Surgical's Fifth Generation da Vinci System Receives CE Mark
by Zacks Equity Research
ISRG secures CE mark for its da Vinci 5 system, unlocking European access to its most advanced surgical platform yet.